Senior Principal Scientist, Medicinal Chemistry

Let’s build the future of medicine—together. Senior Principal Scientist, Medicinal Chemistry Hyderabad, India | Full-Time YOUR ROLE As a Senior Principal Scientist, Medicinal Chemistry at Enveda, you will independently drive lead optimisation programmes — designing novel molecules, interpreting SAR, and shaping drug discovery strategy across multiple programmes. You will work at the intersection of synthetic chemistry, DMPK, biology, and AI-enabled design while mentoring the next generation of medicinal chemists. Reporting to the Director/AVP of Chemistry, your scientific ownership will directly advance our mission to deliver hope to patients everywhere. WHAT YOU'LL DO Independently design novel molecules, interpret SAR/SPR, and generate design hypotheses to drive lead optimisation programmes Integrate biology, DMPK, and AI insights into compound design; use AI-enabled molecular design tools to accelerate discovery Lead multiple discovery programmes with full scientific ownership and present strategy to cross-functional global teams Mentor junior scientists in medicinal chemistry thinking, scientific communication, and decision-making Ensure compliance with Enveda notebook SOPs, internal IP standards, and database requirements WHAT WE'RE LOOKING FOR PhD in Organic or Medicinal Chemistry from a leading research institution with 12-15 years of medicinal chemistry experience in CRO or integrated drug discovery Demonstrated track record of independently driving lead optimisation and delivering preclinical candidates Expert practical skills in synthetic organic chemistry, route design, and SAR/DMPK-informed decision-making Strong rational drug design experience including novelty evaluation and IP awareness Outstanding scientific presentation and communication skills; comfortable representing programmes to global teams We hire for trajectory, not just credentials. If you meet most of the above and care deeply about this problem, we want to hear from you. ABOUT ENVEDA We're a clinical-stage, AI-enabled biotech discovering medicines four times faster than the industry standard. We recently raised $150M in a Series D, reached unicorn status, and advanced our first drug into Phase 2 trials. Forbes named us one of America's Best Startup Employers. Newsweek recognized us as a Top 100 Most Loved Workplace. We're building something rare and we're just getting started!